Genentech and Biogen Idec file complaint against GSK

Pharmaceutical company Genmab has reported that the biotechnology firms have filed a declaratory rel

The complaint, filed at the US district court in California, was regarding patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of Arzerra in the US for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

Genmab said that the US patent No 7,682,612 was issued to Genentech and Biogen Idec on March 23, 2010 and contains a claim to a method of treating CLL with anti-CD20 antibodies, wherein the method does not comprise treatment with radiolabeled anti-CD20 antibodies.

Reportedly, Genmab will, in collaboration with GSK, assess and analyse the claims under the initiated legal action and determine the appropriate action in response to the complaint.